Sickle Cell Disease Forecast, 2027

Dublin, Oct. 20, 2017 -- The "Sickle Cell Disease Forecast in 10 Major Markets 2017-2027" report has been added to Research and Markets' offering.

Sickle cell disease (SCD) is a term comprising clinically relevant haemoglobinopathies caused by mutations in the HBB gene resulting in sickle haemoglobin (HbS). It is the most common genetic disorder worldwide. Clinically, SCD presents a wide variety of forms that range from mild to very severe, depending on the genotype, with a broad range of comorbidities. The most common and severe form, constituting the majority of SCD cases worldwide, is caused by a homozygous inheritance of a single point mutation in the globin subunit and is usually called SCD SS or sickle cell anaemia (SCA).

This report provides the current prevalent population for Sickle cell disease across 10 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Russia, Canada and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Sickle cell disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

These common Sickle cell disease co-morbidities include:

• Vaso-occlusive crisis
• Splenic sequestration
• Chronic anaemia
• Renal failure
• Retinopathy
• Asthma
• Stroke
• Dactylitis
• Pulmonary hypertension
• Acute chest syndrome
• Priapism
  

Reasons to Buy

• Able to quantify patient populations in global sickle cell disease market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of sickle cell disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on sickle cell disease prevalent population.
• Identify sub-populations within sickle cell disease which require treatment.
• Gain an understanding of the specific markets that have the largest number of sickle cell disease patients.

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key Comorbid conditions/features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line prevalence for sickle cell disease

10. Features of Sickle Cell Disease Patients
10.1 Combinations of HBB alleles in SCD patients

11. Comorbid conditions of SCD patients

12. Abbreviations used in the report

13. Patient-Based Offering

14. Online Pricing Data and Platforms

15. References

16. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/qd653m/sickle_cell

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Hematological Drugs